BioCryst (BCRX) Gets a Buy from Wedbush
In a report released today, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of $21.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
According to TipRanks, Chico is a 5-star analyst with an average return of 11.6% and a 51.56% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, BioCryst, and Denali Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $19.27 average price target.
Based on BioCryst’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159.4 million and a net profit of $12.9 million. In comparison, last year the company earned a revenue of $117.09 million and had a GAAP net loss of $14.03 million
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year. Earlier this month, Alane Barnes, the CLO of BCRX sold 50,906.00 shares for a total of $367,032.26.
Read More on BCRX:
